Replies to post #5507 on InVivo Therapeutics Holdings Corp (NVIVQ)

[Perkin78]

I saw it too. It is in the news feed of my Etrade account. Looks like Aquire Media is the source.. I don't have a link to provide.

There are plenty of developmental biotech companies that trade that hi without earnings. I'm sure you know that already. I'm also sure you know these types of companies do not trade on earnings but rather on potential and upcoming catalysts.

And we have those in spades.

[MDizzle]

Invivo Therapeutics Holdings Corp (NVIV) Coverage Initiated by Analysts at Raymond James Financial Inc.

Posted by Carolyn Dwyer on Jul 7th, 2016

Invivo Therapeutics Holdings Corp

Equities research analysts at Raymond James Financial Inc. started coverage on shares of Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) in a research report issued to clients and investors on Thursday. The firm set a “strong-buy” rating and a $13.00 price target on the stock. Raymond James Financial Inc.’s price objective suggests a potential upside of 127.27% from the stock’s previous close.

Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) opened at 5.72 on Thursday. Invivo Therapeutics Holdings Corp has a 12 month low of $3.50 and a 12 month high of $17.19. The stock’s market capitalization is $182.51 million. The firm’s 50-day moving average is $6.30 and its 200 day moving average is $6.09.

Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) last issued its earnings results on Friday, May 6th. The company reported ($0.20) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.26) by $0.06. During the same quarter last year, the firm earned ($0.24) EPS. On average, equities analysts anticipate that Invivo Therapeutics Holdings Corp will post ($1.07) earnings per share for the current year.